
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical is well-positioned in the US market, which accounts for over 60% of its sales. It has a diverse portfolio with strong revenue streams from consumables, infusion systems, and vital care. Despite some potential risks, the company's recent acquisitions of Hospira Infusion Systems and Smiths Medical have solidified its position as a top player in the infusion therapy industry and could lead to further growth and expansion opportunities.
Bears say
ICU Medical is facing challenges related to its recent acquisitions, with a large portion of its revenue coming from the U.S. market and a significant portion of its products running on separate platforms, causing inefficiencies and a disadvantage in the market. Additionally, rising oil prices and a strengthening Mexican peso are pressuring the company's costs, and an outstanding FDA warning letter could delay product approvals and add regulatory risks. Lastly, the company's exposure to oil prices and tariffs, along with a decrease in free cash flow, may limit its ability to conduct share repurchases for EPS growth.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares